Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation - Concepedia

Concepedia

Publication | Open Access

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

DOI Full Paper Access

30

Citations

28

References

2017

Year

Amir T. Fathi, Traci M. Blonquist, Daniela Hernandez, Philip C. Amrein, Karen K. Ballen, Malgorzata McMasters, David Avigan, Robin Joyce, Emma Logan, Gabriela Hobbs,

Abstract

Cabozantinib is well tolerated in AML patients at an MTD of 40 mg daily and is a potent inhibitor of FLT3/ITD- and F691 TKD-altered tyrosine kinases. Cancer 2018;124:306-14. © 2017 American Cancer Society.

References

	Year	Citations

Page 1